2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2957

Socioeconomic Differences in Opioid Use By People with Inflammatory Arthritis
Abstract Number: 2958

Multi-Site Study Evaluating Performance on Lupus Nephritis Quality Measures
Abstract Number: 2959

Development of a Set of Potentially Preventable Adverse Conditions Specific to Lupus: A Delphi Consensus Study
Abstract Number: 2960

Evaluation of Performance Measures Reveals Delays and Sub-Optimal Access to Rheumatology Care and Treatment
Abstract Number: 2961

Differences in Healthcare Transition Views, Practices, and Barriers Among North American Pediatric Rheumatology Providers from 2010 to 2018
Abstract Number: 2962

Diagnostic Accuracy of Gout in Electronic Health Records and the Role of Rheumatology Electronic Consults
Abstract Number: 2963

Improving Clinically Inactive Disease in Patients with Juvenile Idiopathic Arthritis- a Quaternary Center Experience
Abstract Number: 2964

Detection of Uric Acid Crystals in the Vasculature of Patients with Gout Using Dual-Energy Computed Tomography
Abstract Number: 2965

Targeting Glucose Metabolism in the Murine Air Pouch Model of Acute Gouty Inflammation
Abstract Number: 2966

Ultrasound Shows Rapid Reduction of Uric Load during Treat-to-Target Approach in Gout Patients: Results from a Longitudinal Study
Abstract Number: 2967

Potent Bifunctional Inhibitors of Xanthine Oxidase and URAT1 Block Fructose-Induced Inflammation Via Increase in AMP Kinase Activity
Abstract Number: 2968

Role of Choline in Gouty Inflammation
Abstract Number: 2969

Allopurinol Dose Escalation Slows Progression of CT Bone Erosion in People with Gout: Imaging Sub-Study of a Randomized Control Trial
Abstract Number: 2970

In Idiopathic Retroperitoneal Fibrosis, Persistent FDG PET Uptake Helps Identifying Patients at Risk for Relapse
Abstract Number: 2971

Rituximab Associated Hypogammaglobulinemia in Autoimmune Disease: Long Term Outcomes

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].